SELLAS Life Sciences rated Strong Buy with imminent catalyst and dual-platform pipeline

SELLAS Life Sciences receives a Strong Buy rating with an imminent catalyst expected. The company's dual-platform pipeline is highlighted as a key strength.

Why it matters: The market has not yet fully appreciated the potential of this pipeline.